-
2 Winners From AACR Flying Under The Radar
Wednesday, April 20, 2016 - 8:11am | 459Read More...The American Association for Cancer Research (AACR) annual meeting is being held in New Orleans this week. Among the companies that presented data in the event are Juno Therapeutics Inc (NASDAQ: JUNO) and Five Prime Therapeutics Inc (NASDAQ: FPRX), two winners that are flying under the radar so...
-
SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position
Wednesday, April 13, 2016 - 1:44pm | 623Read More...The M&A rumors continue to swirl around biotech firm Medivation Inc (NASDAQ: MDVN), and a SunTrust analyst has commented that the latest take-over chatter highlights the value of the company. A Bloomberg report said Medivation has rejected a take-out offer from Sanofi SA (ADR) (NYSE: SNY),...
-
Why Medivation Could Be 'The Next Big Biotech'
Wednesday, April 6, 2016 - 4:32pm | 466Read More...Medivation Inc (NASDAQ: MDVN) could become the next big biotech, according to SunTrust Robinson Humphrey which initiated the coverage of the stock with a Buy rating and said it could be valued at $62 (range $51-$71) in M&A. In a note, analyst Peter Lawson said the company has a $1 billion...
-
Illumina Creates Helix: Here's What It Is, And What It's Worth
Wednesday, August 19, 2015 - 9:44am | 347Read More...The New York Times on Tuesday discussed the creation of Helix, a new gene sequencing venture. The creation of the new company has the backing and support of Illumina, Inc. (NASDAQ: ILMN), along with the investment firms Warburg Pincus and Sutter Hill Ventures. According to the publication, the...
-
Mizuho Reiterates Buy On Exact Sciences, Expects Positive Outcomes On 2 Coming Decisions
Tuesday, July 21, 2015 - 11:14am | 246Read More...In a report published Tuesday, Mizuho analyst Peter Lawson reiterated a Buy rating and price target of $35 on EXACT Sciences Corporation (NASDAQ: EXAS). Two announcements, expected in the fall, are expected to drive Cologuard adoption further. The analyst expects the USPSTF draft guidance and...
-
Numerous Analysts Bullish On VWR Following Quiet Period Expiration
Tuesday, November 11, 2014 - 11:57am | 155Read More...On Tuesday , the analyst quiet period on shares of VWR Corp (NASDAQ: VWR) expired. Following the expiration, analysts at multiple firms initiated bullish coverage on the company. Goldman Sachs: Buy rating; $31 price target. Isaac Ro outlined three catalysts: Accelerating growth in...
-
UPDATE: Mizuho Securities Initiates Coverage On VWR On Multiple Positive Factors
Tuesday, November 11, 2014 - 9:49am | 134Read More...In a report published Tuesday, Mizuho Securities analyst Peter Lawson initiated coverage on VWR Corp (NASDAQ: VWR) with a Buy rating and $27.00 price target. In the report, Mizuho Securities noted, “We are initiating coverage of shares of VWR Corp (VWR) with a Buy rating and a 12-month price target...
-
Mizuho Securities Ponders How CMS Reimbursement Might Affect EXACT Sciences Corporation
Friday, October 10, 2014 - 11:15am | 120Read More...In a report published Friday, Mizuho Securities analyst Peter Lawson reiterated a Buy rating and $22.00 price target on EXACT Sciences Corporation (NASDAQ: EXAS). In the report, Mizuho Securities noted, “Last night CMS issued preliminary reimbursement of $502 for Cologuard, above the approximately...
-
UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play
Friday, September 12, 2014 - 9:39am | 114Read More...In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on Epizyme Inc (NASDAQ: EPZM) with a Buy rating and $35.00 price target. In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of Epizyme with a Buy rating and a price target of $...
-
UPDATE: Mizuho Securities USA Initiates Coverage On NewLink Genetics Corp On Emerging Market Pure Play
Friday, September 12, 2014 - 9:33am | 106Read More...In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on NewLink Genetics Corp (NASDAQ: NLNK) with a Buy rating and $50.00 price target. In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of NewLink Genetics with a Buy rating and...
-
CareDx's 3-Part Bull & 3-Part Bear Cases
Monday, August 11, 2014 - 8:35am | 231Read More...CareDx (NASDAQ: CDNA) was initiated on by four analysts with an average price target of $13.28 (33.5 percent upside). Mizuho has the highest expectations for CareDX, with a $15 price target. In its research report, Mizuho laid out three aspects of the bull and bear cases. Bull Case...
